Becker's Healthcare June 21, 2021
Nearly $50 billion of Medicare Part D costs in 2016 were for drugs that did not undergo a cost-effectiveness analysis, according to a study published June 18 in JAMA Network Open.
Researchers looked at the 250 drugs with the greatest Medicare Part D spending in 2016, and found 46 percent of them did not have a cost-effectiveness...